Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing invitro fertilization and embryo transfer

Taiwanese Journal of Obstetrics and Gynecology

Volumn 50, Issue 4, 2011, Pages 432-435

  Huang, Shang Yu ^a,b   Huang, Hong Yuan ^a,b   Yu, Hsing Tse ^a,b   Wang, Hsin Shin ^a,b   Chen, Chun Kai ^a,b   Lee, Chyi Long ^a,b   Soong, Yung Kuei ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

GnRH antagonist; Long protocol; Modified flexible multiple dose regimen; Pregnancy rate

Indexed keywords

CETRORELIX; FOLLITROPIN; LEUPRORELIN; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EMBRYO TRANSFER; ENDOMETRIUM; FEMALE; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; HUMAN; LOW DRUG DOSE; LUTEAL PHASE; MAJOR CLINICAL STUDY; PREGNANCY RATE;

ADULT; DRUG ADMINISTRATION SCHEDULE; EMBRYO TRANSFER; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE, HUMAN; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INFERTILITY; LEUPROLIDE; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RETROSPECTIVE STUDIES; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 84855227941     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2011.10.006     Document Type: Article

References (19)

1. Hughes J.N., Cédrin Durnerin I.C. Revisiting gonadotropin-releasing hormone agonist protocols and management of poor ovarian response to gonadotropins. Hum Reprod Update 1998, 4:83-101.
2. Albano C., Smitz J., Camus M., Riethmuller-Winzen H., Van Steirteghem A.C., Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997, 67:917-922.
3. Diedrich K., Diedrich C., Santos E., Zoll C., Al-Hasani S., Reissmann T., et al. Suppression of the endogenous luteinizing hormone surge by the gonadotropin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994, 9:788-791.
4. Nikolettos N., Al-Hasani S., Felberbaum R., Demirel L.C., Kupfer W., Montzka P., et al. Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 2001, 97:202-207.
5. Craft I., Gorgy A., Hill J., Menon D., Podsiadly B. Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols?. Hum Reprod 1999, 14:2959-2962.
6. Cheung L.P., Lam P.M., Lok I.H., Chiu T.T., Yeung S.Y., Tjer C.C., et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod 2005, 20:616-621.
7. Al-Inany H., Aboulghar M. GnRH antagonist in assisted reproduction. ACochrane Review. Hum Reprod 2002, 17:874-885.
8. Oberyé J.J., Mannaerts B.M., Huisman J.A., Timmer C.J. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril 1999, 72:1006-1012.
9. Shahar K. Embryo implantation and GnRH antagonists. Hum Reprod. 2000, 15:1881-1883.
10. Meldrum D.R., Cassidenti D.L., Rosen G.F., Yee B., Wisot A.L. Oral contraceptive pretreatment and half dose of ganirelix does not excessively suppress LH and may be an excellent choice for scheduling IUI cycles. J Assist Reprod Genet 2008, 25:417-420.
11. Fauser B.C., Diedrich K., Devroey P. Evian Annual Reproduction Workshop Group 2007. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 2008, 14:1-14.
12. Out H.J., Rutherford A., Fleming R., Tay C.C., Trew G., Ledger W., et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Hum Reprod 2004, 19:90-95.
13. Friedler S., Schenker J.G., Herman A., Lewin A. The role of ultrasonography in the evaluation of endometrial receptivity following assisted reproductive treatments: a critical review. Hum Reprod Update 1996, 2:323-335.
14. European Orgalutran Study Group, Borm G., Mannaerts B. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulation hormone is effective, safe, and convenient: Results of controlled, randomized, multi-centre trial. Hum Reprod 2000, 15:1490-1498.
15. Fluker M., Grifo J., Leader A., Levy M., Meldrum D., Muasher S.J., et al. North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001, 75:38-45.
16. The European and Middle East Orgalutran Study Group Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001, 16:644-651.
17. Valbuena D., Jasper M., Remohí J., Pellicer A., Simón C. Ovarian stimulation and endometrial receptivity. Hum Reprod 1999, 14(Suppl. 2):107-111.
18. Basir G.S., O W.S., Ng E.H., Ho P.C. Morphometric analysis of peri-implantation endometrium in patients having excessively high estadiol concentrations after ovarian stimulation. Hum Reprod. 2001, 16:435-440.
19. Valbuena D., Martin J., de Pablo J.L., Remohí J., Pellicer A., Simón C. Increasing levels of estradiol are deleterious to embryonic implantation because they directly affect the embryo. Fertil Steril. 2001, 76:962-968.